Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Medicure (MCUJF) EBITDA (2016 - 2025)

Medicure has reported EBITDA over the past 17 years, most recently at -$3.2 million for Q4 2025.

  • For Q4 2025, EBITDA fell 698.61% year-over-year to -$3.2 million; the TTM value through Dec 2025 reached -$4.7 million, down 1054.08%, while the annual FY2025 figure was -$5.7 million, 1268.93% down from the prior year.
  • EBITDA for Q4 2025 was -$3.2 million at Medicure, down from -$751340.6 in the prior quarter.
  • Over five years, EBITDA peaked at $1.8 million in Q3 2022 and troughed at -$3.2 million in Q4 2025.
  • A 5-year average of -$197054.3 and a median of $116059.0 in 2023 define the central range for EBITDA.
  • Biggest five-year swings in EBITDA: crashed 5137.39% in 2021 and later surged 239.99% in 2022.
  • Year by year, EBITDA stood at $1.1 million in 2021, then crashed by 96.78% to $36098.4 in 2022, then tumbled by 4263.23% to -$1.5 million in 2023, then skyrocketed by 135.34% to $531160.1 in 2024, then crashed by 698.61% to -$3.2 million in 2025.
  • Business Quant data shows EBITDA for MCUJF at -$3.2 million in Q4 2025, -$751340.6 in Q3 2025, and -$1.3 million in Q2 2025.